Here is an abstract related to their CCR5 inhibitor. Their path to success from a mouse model may well depend on the type of interaction with the CCR5 receptor; I have long felt that Leronlimab’s superiority with AE’s and SAE’s compared to Maraviroc is related to competitive binding. Cytodyn has patents that may also play a role. The mouse is not likely to grab a mike and start complaining about liver dysfunction following administration, humans will object and their trial pathway could end up in the ditch as a result.

Their success in a mouse model just continues to re-affirm the validity of CCR5 blockade for some types of cancer. They are far behind in the development queue. I would like to see Cytodyn partner for cancer so they can get some traction on that indication.

https://www.researchgate.net/publication/3791...ouse_model